Innate Pharma SA
David Magrez is a seasoned professional with extensive experience in biostatistics and data management. Currently serving as Director and Head of Biostatistics & Data Management at Innate Pharma since September 2021, David provides statistical and methodological leadership for clinical development plans and oversees Data Management and Biostatistics staffing and resource allocation. Prior to this role, David held positions such as Biometrics Director at GENFIT, where responsibilities included managing biometric teams and representing statistical methodology in regulatory communications, and RWD Analysis Strategy Manager at Roche, focusing on Real World Data projects. David's career began at ALTIZEM as Head of Statistical and SAS Programming Department and also included significant roles at Servier, managing biostatistics teams and projects in various therapeutic areas. David holds multiple degrees in medical data processing and public health from French universities.
This person is not in any teams
This person is not in any offices
Innate Pharma SA
2 followers
Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.